Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is a Healthcare company (Biotechnology) with a market capitalization of $9.9B. The Maz Rating grades it against the other companies in its sector.
Madrigal Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $427.39, Madrigal Pharmaceuticals, Inc. trades at 7.0x sales and 19.9x book value. Over the last twelve months it generated about $1.4B of revenue and a net loss of $137M. It runs a gross margin of 91.0%, an operating margin of -10.7% and a net margin of -10.9%. It shows return on equity of -27.1%, return on invested capital of -15.6% and a free cash flow yield of -1.7%. On the balance sheet: a debt-to-equity ratio of 0.56 and a current ratio of 3.05. Over the past 52 weeks the share price ranged from $353.54 to $615.00, with a beta of -1.00.
Madrigal Pharmaceuticals, Inc. does not currently pay a dividend.
25 Wall Street analyst ratings cover the stock: 22 Buy, 2 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.